Atara Biotherapeutics (ATRA) vs Neumora Therapeutics (NMRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atara Biotherapeutics (ATRA) has outperformed Neumora Therapeutics (NMRA) over the past year, losing 53.7% versus a loss of 85.7%. Atara Biotherapeutics is the larger company by market cap ($64.5 million vs $63.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | NMRA |
|---|---|---|
| Share price | $6.33 | $0.3339 |
| Market cap | $64.49M | $63.01M |
| 1-day change | -0.16% | -3.78% |
| YTD return | -65.01% | -81.35% |
| 1-year return | -53.73% | -85.67% |
| 5-year return | -98.56% | — |
| Forward P/E | 3.96 | — |
| EPS (TTM) | $-1.12 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $120.77M | — |
| Revenue growth (YoY) | -6.33% | — |
| Net income (latest FY) | $32.69M | $-236.93M |
| Operating margin | 29.69% | — |
| Net margin | 27.07% | — |
| 52-week high | $19.15 | $3.65 |
| 52-week low | $3.92 | $0.301 |
| Distance from 52-week high | -66.94% | -90.85% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +115.96% | +1696.95% |
| Average volume | 35.46K | 1.69M |
| Shares outstanding | 10.19M | 188.69M |
| Employees | 10 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRA has outperformed NMRA by 31.9 percentage points over the past year.
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 63 employees
ATRA vs NMRA FAQ
Which is bigger, Atara Biotherapeutics or Neumora Therapeutics?
Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $64.49M compared with $63.01M for Neumora Therapeutics (NMRA).
Which stock has performed better over the past year, ATRA or NMRA?
ATRA returned -53.73% over the past 12 months, compared with -85.67% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and Neumora Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.